Study of Milnacipran for the Treatment of Fibromyalgia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Collaborator: Cypress Bioscience, Inc.
• Treatments: Levomilnacipran; Milnacipran

Criteria

Inclusion Criteria:

• diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria

Exclusion Criteria:

• psychiatric illness,

• depression,

• suicidal risk,

• substance abuse,

• pulmonary dysfunction,

• renal impairment,

• active cardiac disease,

• liver disease,

• autoimmune disease,

• cancer,

• inflammatory bowel disease